Health Economics›Breast cancer›Adjuvant therapy sequential regimens

Adjuvant therapy sequential regimens

Breast cancer · 81 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FEC-THP (Docetaxel) Variant #03	ERBB2	R 86 369	21d	—	—	17	R 515 126 PFS proxy	1
ddEC-THP (Docetaxel) Variant #01	ERBB2	R 86 268	21d	—	—	17	R 514 721 PFS proxy	1
EC-THP (Docetaxel) Variant #01	ERBB2	R 85 628	21d	—	—	17	R 512 161 PFS proxy	1
ddAC-THP (Docetaxel) Variant #01	ERBB2	R 84 072	21d	—	—	17	R 505 937 PFS proxy	1
AC-THP (Docetaxel) Variant #01	ERBB2	R 84 072	21d	—	—	17	R 505 937 PFS proxy	1
FEC-THP (Paclitaxel) Variant #01	ERBB2	R 82 991	21d	—	—	17	R 514 273 PFS proxy	1
ddEC-THP (Paclitaxel) Variant #01	ERBB2	R 82 910	21d	—	—	17	R 513 950 PFS proxy	1
EC-THP (Paclitaxel) Variant #01	ERBB2	R 82 910	21d	—	—	17	R 513 950 PFS proxy	1
FAC-THP (Docetaxel) Variant #01	ERBB2	R 81 768	21d	—	—	17	R 505 745 PFS proxy	1
ddAC-THP (Paclitaxel) Variant #01	ERBB2	R 80 714	21d	—	—	17	R 505 165 PFS proxy	1
AC-THP (Paclitaxel) Variant #01	ERBB2	R 80 714	21d	—	—	17	R 505 165 PFS proxy	1
FAC-THP (Paclitaxel) Variant #01	ERBB2	R 80 682	21d	—	—	17	R 504 325 PFS proxy	1
iddEnPC Variant #01	—	R 56 900	14d	—	—	~3	~R 170 700 indirect	—
TH-FEC (Docetaxel) Variant #01	ERBB2	R 32 698	21d	—	—	~3	~R 55 919 indirect	—
VH-FEC Variant #01	ERBB2	R 31 150	21d	—	—	~3	~R 51 272 indirect	—
ddAC-ddTH (Paclitaxel) Variant #01	ERBB2	R 25 509	14d	—	—	~45	~R 256 680 indirect	—
FEC-TH (Docetaxel) Variant #01	ERBB2	R 22 275	21d	—	—	17	R 106 220 PFS proxy	1
EC-TH (Docetaxel) Variant #01	ERBB2	R 22 194	21d	—	—	17	R 108 919 PFS proxy	1
ddEC-TH (Docetaxel) Variant #01	ERBB2	R 22 194	21d	—	—	17	R 108 919 PFS proxy	1
ddAC-TH (Docetaxel) Variant #01	ERBB2	R 19 998	21d	—	—	17	R 100 135 PFS proxy	1
FEC-TH (Paclitaxel) Variant #01	ERBB2	R 18 917	21d	—	—	17	R 105 449 PFS proxy	1
ddEC-TH (Paclitaxel) Variant #01	ERBB2	R 18 836	21d	—	—	17	R 108 148 PFS proxy	1
EC-TH (Paclitaxel) Variant #01	ERBB2	R 18 836	21d	—	—	17	R 108 148 PFS proxy	1
ddFEC-ddTH (Docetaxel) Variant #01	ERBB2	R 18 420	21d	—	—	~12	~R 92 424 indirect	—
AC-TH (Docetaxel) Variant #01	ERBB2	R 17 725	21d	—	—	17	R 100 784 PFS proxy	2
FAC-TH (Docetaxel) Variant #01	ERBB2	R 17 694	21d	—	—	17	R 99 943 PFS proxy	1
AC-TH (Paclitaxel) Variant #01	ERBB2	R 16 640	21d	—	—	17	R 99 363 PFS proxy	3
ddAC-TH (Paclitaxel) Variant #01	ERBB2	R 16 640	21d	—	—	17	R 99 363 PFS proxy	1
FAC-TH (Paclitaxel) Variant #01	ERBB2	R 16 608	21d	—	—	17	R 98 523 PFS proxy	1
FEC-H Variant #01	ERBB2	R 16 569	21d	—	—	~17	~R 104 100 indirect	—
TC-H (Docetaxel) Variant #01	ERBB2	R 16 481	21d	—	—	~17	~R 98 729 indirect	—
EC-H Variant #01	ERBB2	R 16 385	21d	—	—	~17	~R 98 344 indirect	—
T-H (Docetaxel) Variant #01	ERBB2	R 16 331	21d	—	—	~17	~R 98 128 indirect	—
CMF-H Variant #01	ERBB2	R 14 791	21d	—	—	~17	~R 93 433 indirect	—
T-H (Paclitaxel) Variant #01	ERBB2	R 14 671	21d	—	—	~17	~R 96 383 indirect	—
AC-H Variant #01	ERBB2	R 10 143	21d	—	—	~51	~R 246 766 indirect	—
ECD-GC Variant #01	TNBC	R 9 647	21d	—	—	~4	~R 38 588 indirect	—
iddEPC Variant #01	—	R 5 631	14d	—	—	3	R 16 894 PFS proxy	1
D-FEC Variant #01	—	R 5 432	21d	—	—	3	R 16 295 PFS proxy	1
D-FEC Variant #01	TNBC	R 5 432	21d	—	—	3	R 16 295 PFS proxy	1
D-FEC Variant #01	ERBB2	R 5 432	21d	—	—	3	R 16 295 PFS proxy	1
FEC-D Variant #01	—	R 5 432	21d	—	29.0 mo	3	R 16 295 PFS proxy	1
FEC-D Variant #01	TNBC	R 5 432	21d	—	29.0 mo	3	R 16 295 PFS proxy	1
EC-D Variant #01	—	R 5 248	21d	—	—	4	R 20 991 PFS proxy	1
EC-D Variant #01	TNBC	R 5 248	21d	—	—	4	R 20 991 PFS proxy	1
TX-CEX Variant #01	TNBC	R 5 228	21d	—	—	6	R 18 800 PFS proxy	1
TX-CEX Variant #01	—	R 5 228	21d	—	—	6	R 18 800 PFS proxy	1
E-D Variant #01	—	R 5 225	28d	—	—	3	R 15 676 PFS proxy	1
TH-FEC (Docetaxel, SC Trastuzumab) Variant #01 Partial	ERBB2	R 4 965	21d	—	—	~3	~R 14 895 indirect	—
D-EC Variant #01	—	R 4 889	21d	—	—	~4	~R 19 556 indirect	—
ddEC-ddD Variant #01	—	R 4 599	14d	—	—	~4	~R 18 394 indirect	—
ddEC-T Variant #01	—	R 4 331	21d	—	—	6	R 23 372 PFS proxy	1
ddFEC-ddD Variant #01	—	R 4 270	14d	—	—	~4	~R 17 082 indirect	—
V-FEC Variant #01	ERBB2	R 3 947	21d	—	—	~3	~R 8 639 indirect	—
V-FEC Variant #01	—	R 3 947	21d	—	—	~3	~R 8 639 indirect	—
EP-ddCMF Variant #01	—	R 3 825	21d	—	—	~4	~R 14 783 indirect	—
AC-D Variant #01	—	R 3 692	21d	—	—	4	R 14 767 PFS proxy	2
AC-D Variant #01	ERBB2	R 3 692	21d	—	—	4	R 14 767 PFS proxy	2
ddEC-ddT Variant #01	—	R 3 633	14d	—	—	4	R 14 534 PFS proxy	2
E-X Variant #01	—	R 3 602	21d	—	—	~4	~R 14 409 indirect	—
FEC-P Variant #01	—	R 3 162	21d	—	—	~8	~R 15 585 indirect	—
T-FEC Variant #01	—	R 3 122	21d	—	—	~12	~R 17 385 indirect	—
EC-CMF Variant #01	—	R 3 099	28d	—	—	~4	~R 11 624 indirect	—
ddE-iddCMF Variant #01	—	R 3 077	14d	—	—	~4	~R 11 791 indirect	—
E-CMF Variant #01	—	R 3 077	21d	—	—	4	R 12 308 PFS proxy	3
T-ddEC Variant #01	TNBC	R 2 938	14d	—	—	~12	~R 16 649 indirect	—
AT-CMF Variant #01	—	R 2 811	28d	—	—	~4	~R 11 246 indirect	—
ddEC-ddCMF Variant #01	—	R 2 688	14d	—	75.9 mo	4	R 10 390 PFS proxy	—
EC-T Variant #01	—	R 2 554	21d	—	—	12	R 15 113 PFS proxy	2
CMF-E Variant #01	—	R 2 128	21d	—	—	~6	~R 9 186 indirect	—
ddAC-ddT Variant #01	—	R 2 077	14d	—	—	~6	~R 12 464 indirect	—
ddA-ddT-ddC Variant #01	—	R 2 077	14d	—	—	~4	~R 8 309 indirect	—
AC-T Variant #01	TNBC	R 2 077	21d	—	—	4	R 8 309 PFS proxy	2
AC-T Variant #01	—	R 2 077	21d	—	—	4	R 8 309 PFS proxy	2
AC-T Variant #01	ERBB2	R 2 077	21d	—	—	4	R 8 309 PFS proxy	2
FAC-MV Variant #01	—	R 2 065	28d	—	—	~6	~R 9 173 indirect	—
A-CMF Variant #01	—	R 1 562	28d	—	—	~4	~R 6 247 indirect	—
AC-CMF Variant #01	—	R 1 543	28d	—	—	~4	~R 5 399 indirect	—
FAC-T Variant #01	—	R 1 448	21d	—	—	~8	~R 8 729 indirect	—
ddAC-T Variant #01	—	R 1 382	14d	—	—	~12	~R 10 425 indirect	—
T-ddAC Variant #01	TNBC	R 1 382	14d	—	—	~12	~R 10 425 indirect	—

81 of 81 regimens shown